GlassScriptPhysician profile
John P Olarte
NPI 1538278593
$1,392.83
in general payments reported to CMS, 2019-2025
20 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2022: $318 · 2023: $461 · 2024: $163 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $484.23 | 2022-2025 | Caplyta |
| Abbvie INC. | $109.77 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $104.54 | 2022 | |
| Allergan, INC. | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $85.34 | 2019-2023 | Spravato |
| Alkermes, INC. | $67.28 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $54.38 | 2022-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $45.03 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $43.39 | 2022-2025 | |
| Corium, LLC | $41.48 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $37.36 | 2023-2024 | Sunosi |
| Neos Therapeutics, LP | $34.20 | 2019-2022 | |
| Almatica Pharma LLC | $33.66 | 2024 | Loreev Xr |
| Tris Pharma INC | $33.51 | 2022-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $24.99 | 2022-2023 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $21.83 | 2025 | Jornay Pm |
| Brainsway USA INC | $19.22 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.63 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $18.56 | 2025 | Hetlioz, Fanapt |
| Noven Therapeutics, LLC | $15.43 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Olarte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.